Literature DB >> 23556440

Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Amy L Stark, M Eileen Dolan.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23556440      PMCID： PMC4075127          DOI： 10.2217/pgs.13.32

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  22 in total

1.  Evaluation of genetic variation contributing to differences in gene expression between populations.

Authors:  Wei Zhang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; R Stephanie Huang; Tyson A Clark; Tina X Chen; Anthony C Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
Journal:  Am J Hum Genet       Date:  2008-02-28       Impact factor: 11.025

Review 2.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

3.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

4.  Population genomics of human gene expression.

Authors:  Barbara E Stranger; Alexandra C Nica; Matthew S Forrest; Antigone Dimas; Christine P Bird; Claude Beazley; Catherine E Ingle; Mark Dunning; Paul Flicek; Daphne Koller; Stephen Montgomery; Simon Tavaré; Panos Deloukas; Emmanouil T Dermitzakis
Journal:  Nat Genet       Date:  2007-09-16       Impact factor: 38.330

5.  A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.

Authors:  Chad C Brown; Tammy M Havener; Marisa W Medina; J Todd Auman; Lara M Mangravite; Ronald M Krauss; Howard L McLeod; Alison A Motsinger-Reif
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

6.  Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Authors:  Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

7.  Genetic analysis of radiation-induced changes in human gene expression.

Authors:  Denis A Smirnov; Michael Morley; Eunice Shin; Richard S Spielman; Vivian G Cheung
Journal:  Nature       Date:  2009-04-06       Impact factor: 49.962

8.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

Authors:  Deborah French; Wenjian Yang; Cheng Cheng; Susana C Raimondi; Charles G Mullighan; James R Downing; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

9.  Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.

Authors:  Marisa Wong Medina; Feng Gao; Weiming Ruan; Jerome I Rotter; Ronald M Krauss
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

10.  Systems analysis of EGF receptor signaling dynamics with microwestern arrays.

Authors:  Mark F Ciaccio; Joel P Wagner; Chih-Pin Chuu; Douglas A Lauffenburger; Richard B Jones
Journal:  Nat Methods       Date:  2010-01-24       Impact factor: 28.547
View more
  7 in total

1.  Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Authors:  M Eileen Dolan; Michael L Maitland; Peter H O'Donnell; Yusuke Nakamura; Nancy J Cox; Mark J Ratain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 2.  Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.

Authors:  Adrian J Green; Benedict Anchang; Farida S Akhtari; David M Reif; Alison Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2021-05-28       Impact factor: 2.638

3.  Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.

Authors:  Laurent Chouchana; Ana Aurora Fernández-Ramos; Florent Dumont; Catherine Marchetti; Irène Ceballos-Picot; Philippe Beaune; David Gurwitz; Marie-Anne Loriot
Journal:  Genome Med       Date:  2015-04-18       Impact factor: 11.117

4.  Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.

Authors:  Lata Chauhan; Gregory D Jenkins; Neha Bhise; Tanya Feldberg; Taraswi Mitra-Ghosh; Brooke L Fridley; Jatinder K Lamba
Journal:  BMC Genomics       Date:  2015-06-30       Impact factor: 3.969

5.  Genetic screening reveals a link between Wnt signaling and antitubulin drugs.

Authors:  A H Khan; J S Bloom; E Faridmoayer; D J Smith
Journal:  Pharmacogenomics J       Date:  2015-07-07       Impact factor: 3.550

6.  Gene expression and proliferation biomarkers for antidepressant treatment resistance.

Authors:  J Breitfeld; C Scholl; M Steffens; G Laje; J C Stingl
Journal:  Transl Psychiatry       Date:  2017-03-14       Impact factor: 6.222

7.  Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose.

Authors:  Michael A Grassi; Vidhya R Rao; Siquan Chen; Dingcai Cao; Xiaoyu Gao; Patricia A Cleary; R Stephanie Huang; Andrew D Paterson; Rama Natarajan; Jalees Rehman; Timothy S Kern
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.